English
Afrikaans
Albanian
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bulgarian
Catalan
Chinese (Simplified)
Chinese (Traditional)
Croatian
Czech
Danish
Dutch
Estonian
Filipino
Finnish
French
Galician
Georgian
German
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Malay
Maltese
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Thai
Turkish
Ukrainian
Urdu
Vietnamese
Welsh
YiddishFirst Approval of Gene Therapy in Hemophilia
Watch the Latest Conference Briefs to Learn More
Updates on Three Ongoing Clinical Trials on Adults with Severe Hemophilia B
Steven W. Pipe, MD...
Rapid Clearance of Vector Following AAV-Mediated FVIII Gene Transfer in the Phase I/II Trial of SPK-8011 in People With Hemophilia A
Benjamin J. Samelson Jones, MD, PhD...
Relationship Between Transgene-Produced FVIII and Bleeding Rates 2 Years After Gene Transfer With Valoctocogene Roxaparvovec: Results From Gener8-1
Johnny Mahlangu, BSc, MBBCh, MMed, FCPath...
Elucidating the Mechanism Behind the AAV-Derived Factor VIII Assay Discrepancy
Anna Sternberg, PhD...
Stabilin-2 Promoter Modulates the Immune Response to FVIII After Lentiviral Vector Delivery in Hemophilic Mice
Antonia Follenzi, MD, PhD...
Impact of Valoctocogene Roxaparvovec Gene Transfer for Severe Haemophilia A on Health-related Quality of Life
Johnny Mahlangu, BSc, MBBCh, MMed, FCPath...
